Dibutepinephrine (Anaphylm)

Small molecule

Filedunder review

Evidence outlook · regulatory review

Anaphylaxis: application under FDA review, decision date 2027-03-16

FDA accepts the Anaphylm NDA resubmission (Class 2) (2026-10-15). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Other / comorbidity
NCT06527937 · Aquestive Therapeutics
2024-07-17 – 2024-10-13 · Allergic Reaction
What this study did
Phase 1 (1)
Other / comorbidity
NCT07703982 · Aquestive Therapeutics
2024-12-26 – 2025-05-21 · Allergic Reaction
What this study did

Competitive landscape

Other Alpha- and beta-adrenergic receptors (agonist) drugs

Epinephrine. Compare all 2 Alpha- and beta-adrenergic receptors (agonist) drugs

1 other tracked programme targets this mechanism.

This drug's own stage for Anaphylaxis: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dibutepinephrine (Anaphylm): this drugStage not on recordSmall moleculeAlpha- and beta-adrenergic receptors (agonist)not yet gradedNo reviewed efficacy summary in this indication
Epinephrine (neffy)ApprovedSmall moleculeAlpha- and beta-adrenergic receptors (agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

16 March 2027FDA action datePDUFA goal date for the Anaphylm NDA resubmission
US, FDA · Aquestive Therapeutics, Inc. · Source ↗

Recent

15 October 2026Filing acceptedFDA accepts the Anaphylm NDA resubmission (Class 2)
US, FDA · Aquestive Therapeutics, Inc. · Source ↗
September 2026Filing submittedAnaphylm NDA resubmitted after complete response letter
US, FDA · Aquestive Therapeutics, Inc. · Source ↗
10 August 2026Topline resultTopline human factors and pharmacokinetic study results for Anaphylm
Aquestive Therapeutics, Inc. · Source ↗
31 January 2026FDA action dateAnaphylm NDA PDUFA target action date
US, FDA · Aquestive Therapeutics, Inc. · Source ↗
30 January 2026Complete response letterFDA issues complete response letter for Anaphylm
US, FDA · Aquestive Therapeutics, Inc. · Source ↗
16 June 2025Filing acceptedFDA accepts Anaphylm NDA
US, FDA · Aquestive Therapeutics, Inc. · Source ↗
March 2025Filing submittedOriginal Anaphylm NDA submitted to the FDA
US, FDA · Aquestive Therapeutics, Inc. · Source ↗